Novo Nordisk spikes as novel obesity drug causes up to 22% of weight loss Novo Nordisk spikes as novel obesity drug causes up to 22% of weight loss Post Contentnvo, llyRead More You might also be interested in reading Synovus Q4 2024 Earnings Preview. January 24, 2025 In Mainstream ← Previous post Next post →